Insider Selling: Alzamend Neuro (NASDAQ:ALZN) Director Sells $160,803.32 in Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 65,903 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $2.44, for a total transaction of $160,803.32. Following the transaction, the director owned 8,260 shares of the company’s stock, valued at approximately $20,154.40. This trade represents a 88.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Alzamend Neuro Trading Up 2.4%

ALZN stock opened at $2.53 on Monday. Alzamend Neuro, Inc. has a 12-month low of $2.06 and a 12-month high of $17.10. The business’s 50-day moving average is $2.40 and its 200 day moving average is $4.05.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro as of its most recent SEC filing. Institutional investors and hedge funds own 49.61% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on ALZN shares. Ascendiant Capital Markets reduced their price objective on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. Weiss Ratings reiterated a “sell (e)” rating on shares of Alzamend Neuro in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alzamend Neuro currently has a consensus rating of “Hold” and an average price target of $42.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.